What is the difference between fatty liver and cirrhosis?

Fatty liver is the accumulation of fat in liver cells and is largely reversible with lifestyle modification in the early stages. Cirrhosis is the end result of years of progressive scarring, in which normal liver tissue has been extensively replaced by scar tissue that cannot regenerate. Fatty liver does not automatically lead to cirrhosis, but it is the starting point of a progression that, in a subset of patients, does reach that stage. The difference in clinical urgency is significant: fatty liver in most cases is a lifestyle condition requiring monitoring and metabolic management, while cirrhosis, once decompensated, may require transplant evaluation.

Can cirrhosis be reversed?

Compensated cirrhosis cannot be reversed in the sense of returning the liver to a completely normal state, but its progression can be slowed or halted if the underlying cause is removed or treated effectively. In some patients, particularly those with alcohol-related cirrhosis who achieve complete abstinence, or those with viral hepatitis who achieve virological clearance, some degree of liver improvement is possible. However, once decompensation occurs, the trajectory changes fundamentally, and medical management alone is unlikely to restore adequate function long-term. This is why the focus should be on identifying the underlying cause as early as possible and treating it before irreversible damage accumulates.

Is fatty liver dangerous if the liver enzymes are normal?

Normal liver enzymes do not rule out significant liver disease. A substantial proportion of patients with active NASH and even with advanced fibrosis have entirely normal ALT and AST levels on standard blood tests. Liver enzymes reflect hepatocyte injury, not liver function, and not the presence of fibrosis. Patients with fatty liver and metabolic risk factors (diabetes, obesity, high triglycerides, hypertension) should have their liver disease monitored with imaging (ultrasound or FibroScan) rather than relying solely on blood tests to determine whether the disease is progressing.

When should a patient with cirrhosis be referred to a transplant surgeon?

The first episode of decompensation, meaning the first occurrence of ascites, variceal bleeding, hepatic encephalopathy, or persistent jaundice in a patient with known cirrhosis, is the point at which transplant surgical evaluation should begin. This does not mean a transplant will follow immediately. It means the patient's trajectory, fitness, donor options, and MELD score can be assessed while options are still available, rather than after a second or third crisis has narrowed them.

What is refractory ascites and why does it matter surgically?

Refractory ascites is ascites that no longer responds to maximum doses of diuretics combined with sodium restriction, or that recurs so rapidly after drainage that adequate medical control is not achievable. It matters surgically because it is an independent indicator of poor prognosis in cirrhosis, associated with a one-year survival of approximately 50%, and is an accepted indication for transplant listing regardless of MELD score. Patients with refractory ascites requiring regular large-volume paracentesis should be under transplant surgical evaluation without delay.

What is hepatocellular carcinoma and how is it treated surgically?

Hepatocellular carcinoma (HCC) is primary liver cancer arising almost exclusively in chronically diseased, usually cirrhotic, liver. In India it most commonly arises on a background of hepatitis B, hepatitis C, or alcohol-related cirrhosis. Surgical options include resection (removing the tumour), transplantation (removing both the tumour and the underlying diseased liver), and in some cases, ablation of the tumour. The right approach depends on tumour size and number, the degree of cirrhosis and portal hypertension, and the patient's overall fitness. Decisions about HCC in a cirrhotic liver require a surgeon with expertise in both transplant surgery and HPB surgery, since the optimal treatment often sits at the intersection of both specialties.

Can liver disease caused by alcohol be treated with transplantation?

Yes, in selected patients. Alcohol-related liver disease is a recognised indication for liver transplantation in appropriate candidates. The assessment process for these patients typically includes an evaluation by an addiction specialist and a requirement for documented abstinence, though the specific duration of required abstinence varies between programmes and individual clinical circumstances. Each case is evaluated on its merits, and a history of alcohol-related liver disease does not automatically disqualify a patient from transplant consideration.

What are the stages of liver cirrhosis and when does each become serious?

Liver disease progresses through four stages: fatty liver, inflammation (NASH), fibrosis, and cirrhosis. Cirrhosis itself has two phases, compensated, where the liver continues functioning despite scarring, and decompensated, where complications appear. The compensated phase can last years with proper management. Decompensation, marked by ascites, variceal bleeding, encephalopathy, or jaundice, is the turning point that requires transplant surgical evaluation. Common causes driving this progression in India include hepatitis B, hepatitis C, alcohol-related liver disease, and NAFLD linked to obesity and diabetes.

Liver Disease Stages in India: Signs You Shouldn't Miss

Liver disease is among the most common serious health conditions in India, yet it is also one of the most frequently misunderstood. Most patients with liver disease will never need surgery. Many will not even need a specialist. However, a significant minority progress to a stage where the liver can no longer compensate. When irreversible liver failure develops, medical treatment may control individual complications, but liver transplantation may become the only definitive treatment for appropriately selected patients.

The difficulty is that liver disease is largely silent in its early stages. It does not hurt. It does not announce itself with obvious symptoms. By the time a patient develops jaundice, abdominal swelling, or vomiting blood, the disease has often been present for years, sometimes decades.

This guide covers the full progression of liver disease in India, from the earliest stage of fatty liver through to cirrhosis, liver failure, and liver cancer. It explains when a physician can manage the condition conservatively, when a surgeon must be involved, which warning signs patients and families commonly miss, and why the timing of that surgical referral matters as much as the referral itself.

One of the commonest situations Dr. Manikandan Kathirvel sees in practice is a family arriving for transplant evaluation believing that the liver disease has developed suddenly over the previous few weeks. In reality, the process has often been progressing silently for many years, and the recent jaundice, ascites, confusion, or bleeding is simply the point at which the liver has lost its ability to compensate.

This is why he tells patients that a diagnosis of fatty liver should not create panic, but it should not be ignored either. The important question is not simply whether there is fat in the liver, but whether there is inflammation or fibrosis developing underneath it. Identifying that progression early gives patients and their care team an opportunity to intervene long before transplantation ever becomes necessary.

Key Takeaways

Liver disease progresses through a well-defined sequence, fatty liver to inflammation to fibrosis to cirrhosis, and each stage carries a different risk profile, management approach, and surgical threshold.
Recent Indian data suggest that metabolic fatty liver disease affects approximately 4 in 10 adults, although prevalence varies considerably according to population, geography, obesity, diabetes, and the method used to diagnose it.
The transition from compensated to decompensated cirrhosis is the critical clinical turning point. It is this event, not the cirrhosis diagnosis itself, that typically prompts surgical evaluation.
Several warning signs that indicate the liver is beginning to fail are commonly misattributed to other causes, including fatigue, mild confusion, and abdominal bloating. By the time jaundice or bleeding appears, the liver disease is usually advanced.
Liver cancer arising in cirrhosis (hepatocellular carcinoma) requires a specialist with dual expertise in liver transplant and HPB surgery to determine whether resection, transplant, or another approach gives the best chance of long-term survival.

What This Guide Covers

The Progression of Liver Disease: Fatty Liver to Cirrhosis
When a Physician Manages and When a Surgeon Must Be Involved
Key Warning Signs Patients and Families Commonly Miss
Acute Liver Failure vs. Chronic Liver Disease
Jaundice, Ascites, and Hepatocellular Carcinoma: Explained Surgically
If You’re Considering a Surgical Evaluation
About Dr. Manikandan Kathirvel
Frequently Asked Questions

The Progression of Liver Disease: Fatty Liver to Cirrhosis

With the exception of acute liver failure, which is covered separately below, most serious liver conditions develop over years or decades through a predictable sequence. Understanding where a patient sits in that sequence is the starting point for every clinical decision.

Stage 1: Fatty Liver (Steatosis)

Fatty liver is the accumulation of fat within liver cells beyond what the organ normally stores. It is the most common liver condition in India and globally, and in the vast majority of cases it causes no symptoms at all.

In urban screening programmes across India, fatty liver is detected in a high proportion of individuals assessed, reflecting a population already presenting with metabolic risk factors. Population-level cohort data puts MASLD prevalence in India at approximately 32%, based on a meta-analysis of Asian studies.

Fatty liver is not the same as liver failure, and most people with simple steatosis will never develop cirrhosis. However, a proportion develop progressive inflammation and fibrosis, particularly when metabolic risk factors are present.

The critical question is whether the fatty liver remains simple steatosis or progresses to the next stage.

Stage 2: Liver Inflammation (MASH / Steatohepatitis)

In a subset of patients with fatty liver, the fat accumulation triggers an inflammatory response within the liver. This condition is called metabolic dysfunction associated steatohepatitis (MASH)It is at this stage that the liver begins to sustain genuine cellular damage.

MASH is clinically important because it is the stage at which fibrosis, and ultimately cirrhosis, becomes a real risk. It is estimated that approximately 31% of patients with MASLD in India have MASH, representing a substantial burden in absolute numbers given the overall prevalence of fatty liver disease.

MASH often remains asymptomatic. Liver enzymes (ALT, AST) may be mildly elevated on blood tests, but many patients with significant liver inflammation have entirely normal blood tests. This is one of the reasons the disease goes undetected for so long.

Stage 3: Fibrosis

Repeated episodes of liver inflammation cause scar tissue to form within the liver. This scarring is called fibrosis. The liver has some capacity to heal and reverse early fibrosis if the underlying cause is removed, but progressive fibrosis leads irreversibly toward cirrhosis.

Fibrosis is staged from F0 (no fibrosis) to F4 (cirrhosis) using either liver biopsy or non-invasive tests such as FibroScan (a painless scan that measures liver stiffness to estimate fibrosis without requiring a biopsy). Most patients with early fibrosis (F1 to F2) remain under physician care with monitoring, lifestyle modification, and treatment of underlying conditions. Research suggests that the annual fibrosis progression rate in patients with MASH is approximately one stage every seven years, compared with one stage every fourteen years in patients with simple fatty liver without inflammation, meaning the presence of active inflammation significantly accelerates the timeline.

Advanced fibrosis (F3) carries a significantly greater risk of progression and warrants specialist hepatology assessment, closer surveillance, and careful evaluation for complications.

Stage 4: Cirrhosis

Cirrhosis is the end stage of fibrotic progression, in which normal liver tissue has been extensively replaced by scar tissue. The liver’s architecture is distorted, blood flow through the organ is obstructed, and liver function begins to decline.

It is essential to understand that cirrhosis itself is not a single clinical state. It exists in two fundamentally different phases, each with a very different prognosis and clinical trajectory.

Compensated cirrhosis is the earlier phase. The liver is significantly scarred, but it is still managing to perform its essential functions adequately. Many patients with compensated cirrhosis have no symptoms at all and are unaware of their diagnosis. Median survival in compensated cirrhosis is measured in years to over a decade with appropriate management.

Decompensated cirrhosis is the later phase, and it represents the critical turning point. This is when the liver can no longer compensate for the scarring, and specific complications begin to appear. These complications, described in detail below, mark the transition from a condition that physicians can manage conservatively to one that requires surgical evaluation and potentially liver transplantation.

A common misconception is that a patient who feels well with compensated cirrhosis has only mild liver disease. In fact, the liver may already be significantly scarred; it is simply still able to compensate.

What often changes the clinical course is the first episode of ascites, encephalopathy, variceal bleeding, or significant jaundice. Unfortunately, Dr. Manikandan Kathirvel frequently meets patients only after they have had several such admissions. Ideally, that first decompensation should trigger a discussion about prognosis and transplant suitability, even if transplantation is not immediately required.

When Medical Management Is Enough and When Transplant or HPB Surgical Evaluation Becomes Important

This distinction is one of the most practically important in all of liver medicine, and it is frequently misunderstood by patients, families, and even some referring clinicians.

The Physician’s Role in Liver Disease

For the majority of the liver disease spectrum, from fatty liver through MASH and into early fibrosis and even early compensated cirrhosis, the primary care is delivered by a physician: a gastroenterologist or hepatologist. Their role is to identify the underlying cause, treat it where possible, reduce metabolic risk factors, monitor for progression with regular imaging and blood tests, and screen for liver cancer with six-monthly ultrasound in patients with cirrhosis.

A physician will manage ascites with diuretics and sodium restriction, treat hepatic encephalopathy with lactulose and rifaximin, and arrange banding of oesophageal varices to reduce bleeding risk. These are medical interventions that can control complications and improve quality of life significantly.

When a Surgeon Must Be Involved

A surgical opinion becomes necessary when one or more of the following situations arises:

First decompensation event. The first episode of ascites, variceal bleeding, hepatic encephalopathy, or jaundice in a patient with known cirrhosis marks the transition to decompensated cirrhosis. A first decompensation should prompt consideration of transplant evaluation alongside treatment of the immediate complication, particularly when liver dysfunction is significant or the event is likely to recur.

Among adults with compensated cirrhosis, the risk of progression to decompensation or death is approximately 10% per year, and among adults who have experienced their first decompensation, the risk of further liver events or death rises to approximately 32% per year. These are not figures that support a wait-and-watch approach.

Liver cancer in cirrhosis. Hepatocellular carcinoma (HCC) arising in a cirrhotic liver requires a specialist trained in both transplant surgery and HPB (hepato-pancreato-biliary) surgery to determine whether resection, transplant, ablation, or another approach offers the best outcome. These decisions are best made within a multidisciplinary liver team, bringing together hepatology, transplant surgery, HPB surgery, radiology, interventional radiology, oncology, and other specialties as required.

Acute liver failure. Sudden and rapid loss of liver function in a patient without pre-existing liver disease is a medical emergency that requires immediate involvement of a transplant surgical team, as the window for intervention is narrow.

Biliary disease causing secondary liver damage. Conditions affecting the bile ducts, such as primary sclerosing cholangitis, biliary strictures, or recurrent cholangitis, can cause progressive liver damage requiring surgical assessment even before cirrhosis is established.

Any doubt about whether the liver disease is within medical management. A transplant surgical opinion does not commit a patient to surgery. It opens the conversation, allows evaluation of all options, and ensures that if surgery becomes necessary, the patient is not referred too late.

The value of an early transplant assessment is not that every patient will immediately need a transplant. In many patients, the transplant team may conclude that transplantation is not yet necessary and continue medical treatment and surveillance.

The advantage is that the team understands the patient’s liver disease, overall fitness, nutrition, cardiac and kidney function, and potential transplant options before another major deterioration occurs. When patients are referred only during severe infection, renal failure, profound malnutrition, or multiorgan dysfunction, some of the options that might have been available earlier can become considerably more difficult.

Key Warning Signs Patients and Families Commonly Miss

Liver disease has a well-earned reputation for silence. The following symptoms are frequently missed, misattributed, or normalised by patients and families until the disease is advanced.

Fatigue and Muscle Wasting

Persistent, unexplained fatigue is one of the earliest and most consistent symptoms of progressive liver disease. It is almost universally attributed to stress, overwork, poor sleep, or ageing, rather than to the liver.

Alongside fatigue, loss of muscle mass is a feature of chronic liver disease that is clinically significant and frequently overlooked. Patients with cirrhosis lose muscle at a faster rate than healthy individuals, and this muscle wasting (sarcopenia) directly affects their ability to tolerate surgery, recover from transplantation, and maintain quality of life. Nutritional assessment is a standard component of any transplant evaluation for this reason.

Mild Confusion and Personality Change

Early hepatic encephalopathy, the confusion that results from toxins accumulating in the blood when the liver can no longer clear them, is routinely mistaken for depression, dementia, or normal ageing in older patients. Family members may notice subtle personality changes, reduced sharpness, or occasional disorientation long before the clinical signs are overt. These should always prompt liver function assessment in a patient with known liver disease.

Abdominal Bloating

Early ascites, the accumulation of fluid in the abdominal cavity caused by portal hypertension and low albumin, can manifest as what feels like general bloating, a gradual increase in waist size, or a sensation of fullness. It is routinely attributed to dietary factors or weight gain. By the time ascites is clinically obvious, with visible abdominal distension, the liver disease is significantly advanced.

Itching

Persistent itching without a dermatological cause, especially on the palms and soles, can be a sign of bile salt accumulation due to impaired liver function or biliary disease. It is often treated symptomatically for months before the liver connection is made.

Spider Naevi and Palmar Erythema

Small, spider-shaped blood vessel clusters on the skin (spider naevi) and redness of the palms (palmar erythema) are visible physical signs of chronic liver disease that are often noticed but not acted upon. These are clinical signs that any physician examining a patient with risk factors for liver disease should be looking for actively.

Acute Liver Failure vs. Chronic Liver Disease

These are two distinct clinical situations that are often confused by patients and families.

Chronic liver disease develops over years. The liver has time to compensate, and the body adapts to gradually declining function. Cirrhosis and its complications are the end result of this slow progression. Most of the liver disease described in this guide falls under this category.

Acute liver failure is the sudden and rapid loss of liver function in a patient who previously had a normal or near-normal liver. There is no compensatory period. The liver fails within days to weeks, and the consequences, including severe jaundice, bleeding disorders, acute kidney failure, and encephalopathy, can be fatal without urgent intervention.

In India, common causes of acute liver failure include viral hepatitis (especially hepatitis E in pregnant women), drug-induced liver injury (including herbal and traditional remedies), and in some cases, hepatitis B. Unlike chronic liver disease, acute liver failure can strike patients of any age with no prior liver history.

Acute liver failure is a transplant emergency. The evaluation and decision-making window is measured in days, not weeks. Patients with suspected acute liver failure should be transferred immediately to a centre with a liver transplant programme.

Jaundice, Ascites, and Hepatocellular Carcinoma: Explained Surgically

These three conditions represent the most common reasons a patient with liver disease requires a surgical opinion. Each is explained below from the perspective of what the surgeon is assessing and why the surgical decision matters.

Jaundice in Liver Disease

Jaundice, the yellowing of the skin and whites of the eyes, occurs when bilirubin builds up in the bloodstream. In the context of liver disease, jaundice can have several surgical implications:

In patients with cirrhosis, progressive jaundice that does not resolve suggests worsening liver function and may indicate decompensation or the development of hepatocellular carcinoma. A rising bilirubin in a cirrhotic patient is a signal that transplant evaluation should be urgently pursued.

In patients without cirrhosis, jaundice can result from bile duct obstruction by a tumour, gallstone, or stricture. Distinguishing obstructive jaundice from hepatocellular jaundice is critical because the treatment approach is entirely different. Obstructive jaundice from a bile duct tumour or pancreatic head mass may require complex HPB surgery, including Whipple’s procedure, bile duct resection, or liver resection, rather than transplantation.

Ascites

Ascites is the accumulation of fluid in the peritoneal cavity, almost always caused in liver disease by portal hypertension (the elevated pressure in the portal vein system that results from cirrhotic obstruction of blood flow) combined with reduced albumin production by the failing liver.

From a surgical perspective, ascites is significant for several reasons. First, it marks the first episode of decompensation in many patients, signalling the need for transplant evaluation. Second, refractory or recurrent ascites is a marker of advanced decompensated cirrhosis and should prompt transplant evaluation. MELD score alone may sometimes underestimate the clinical severity of these patients, and other treatment options, including repeated large-volume paracentesis or TIPS, may also be considered depending on the individual situation.

Third, large-volume ascites complicates abdominal surgery of all kinds and must be carefully managed before any operative intervention.

Hepatocellular Carcinoma (Liver Cancer Arising in Cirrhosis)

H. Hepatocellular carcinoma (HCC) is one of the most important primary liver cancers. Most HCC develops in patients with chronic liver disease or cirrhosis, although it can also occur in non-cirrhotic livers, particularly in patients with chronic hepatitis B and in a subset of patients with metabolic liver disease

In India, the majority of HCC cases arise on a background of hepatitis B or hepatitis C cirrhosis, alcohol-related cirrhosis, or increasingly, MASH-related cirrhosis.

The surgical management of HCC in cirrhosis is one of the most complex areas of liver surgery, precisely because two problems must be addressed simultaneously: the cancer and the underlying liver disease. The main surgical options are:

Liver resection (removing the tumour with a margin of normal liver) is possible when the tumour is accessible, the remaining liver is healthy enough to sustain function after the resection, and portal hypertension is not severe. Resection carries a higher recurrence rate than transplantation but avoids the need for an organ and does not require long-term immunosuppression.

Liver transplantation removes both the tumour and the underlying cirrhotic liver simultaneously. It offers the potential for cure of both the cancer and the liver disease in a single procedure. The Milan criteria, the internationally accepted benchmark for transplant eligibility in HCC (a single lesion no larger than 5 cm, or up to three lesions none larger than 3 cm, with no vascular invasion or spread), yield a four-year survival rate of approximately 75% and a recurrence rate below 15%. Selected patients outside these conventional limits may also become transplant candidates following successful downstaging, depending on tumour biology, treatment response, and programme-specific criteria.

The choice between resection and transplant for a patient with HCC within the Milan criteria depends on liver function, portal hypertension, tumour biology, donor availability, and the surgeon’s combined expertise across both procedures.

Because the treatment options may include liver resection, transplantation, ablation, locoregional therapy, systemic therapy, or combinations of these approaches, HCC is best assessed within a multidisciplinary liver cancer team with expertise in both HPB surgery and liver transplantation.

When a patient has liver cancer, the the largest tumour is not always the entire problem.The surgical team has to assess both the cancer and the liver in which that cancer has developed.

A small, apparently resectable tumour may be better treated by transplantation in a patient with significant cirrhosis or portal hypertension, whereas another patient with a similar-sized tumour and well-preserved liver function may be an excellent candidate for liver resection. Conversely, some patients initially considered unsuitable for transplantation may become candidates after successful downstaging treatment.

The best decision therefore comes from evaluating tumour biology, liver function, portal hypertension, anatomy, overall fitness, and transplant options together rather than looking at tumour size alone.

For a full discussion of HCC, hilar cholangiocarcinoma, biliary strictures, and other conditions requiring combined transplant and HPB expertise, see HPB Surgery: The Patient’s Guide to Complex Hepatobiliary Surgery.

If You’re Considering a Surgical Evaluation

A surgical evaluation for liver disease does not mean surgery is inevitable. It means an experienced transplant and HPB surgeon can assess where the patient sits in their disease trajectory, whether surgical intervention is needed now or in the future, and what options exist before a crisis makes the decision for everyone.

If any of the conditions described in this guide apply to a family member, fatty liver with metabolic risk, compensated cirrhosis requiring monitoring, a first decompensation event, or a liver cancer diagnosis, early surgical evaluation preserves options that late referral cannot recover. Dr. Manikandan Kathirvel sees patients at Gleneagles Hospital, Chennai. No prior referral is required. Request an Evaluation →

About Dr. Manikandan Kathirvel

Dr. Manikandan Kathirvel is a Consultant HPB, Liver and Pancreas Transplant Surgeon at Gleneagles Hospital, Chennai, specialising in complex hepatobiliary surgery, liver transplantation, pancreas transplantation, and advanced pancreatic surgery.

After completing his postgraduate training in General Surgery with Gold Medal honours, he pursued M.Ch. Gastrointestinal Surgery, graduating with Distinction and Gold Medal. He subsequently completed three years of advanced fellowship training in Multi-Organ Transplantation and Hepatopancreatobiliary (HPB) Surgery at Cambridge University Hospitals NHS Foundation Trust and Royal Free London NHS Foundation Trust, two internationally recognised centres for liver transplantation, complex HPB surgery, and transplant innovation.

Following his fellowship training, he was appointed as a Consultant HPB and Liver Transplant Surgeon at Whittington Health NHS Trust and Royal Free London NHS Foundation Trust in London. During his consultant practice in the United Kingdom, he managed a broad spectrum of complex hepatobiliary, pancreatic, and liver transplant patients. Royal Free London NHS Foundation Trust is one of Europe’s largest liver transplant centres and a major teaching hospital affiliated with University College London (UCL), where he further developed his expertise in advanced liver transplantation, complex HPB surgery, and multidisciplinary liver cancer care.

Dr. Kathirvel holds the FRCS (Transplant Surgery) from the Royal College of Surgeons of Edinburgh and has successfully completed the Certificate of Eligibility for Specialist Registration (CESR, UK), leading to his inclusion on the GMC Specialist Register as a Consultant Surgeon in the United Kingdom.

Throughout his career, he has been associated with nearly 1,000 liver transplant procedures, more than 120 pancreas transplant procedures, and over 2,000 major hepatobiliary and gastrointestinal operations. His clinical experience also includes extensive expertise in living donor liver transplantation, deceased donor liver transplantation, liver resection, pancreatic surgery, complex biliary reconstruction, minimally invasive HPB surgery, and multi-organ retrieval surgery.

His dual training in liver transplantation and complex HPB surgery enables him to provide comprehensive assessment and surgical management across the entire spectrum of liver, biliary, and pancreatic diseases from advanced cirrhosis and liver failure to liver cancer, pancreatic tumours, biliary strictures, and complex conditions where the decision between liver resection, transplantation, or other advanced therapies requires highly specialised expertise.

For his full training history, academic achievements, research contributions, publications, and professional credentials, please visit his Professional Profile.

For his full training history, credentials, and academic background, see Liver Transplant in Chennai: The Complete Patient Guide.

Insights & Resources

Published Date: 19 August 26

Liver Disease in India: From Diagnosis to Surgical Decision

Author

Dr. Manikandan Kathirvel

MBBS, MS, MRCS, M.Ch(GI), FRCS (Transplant Surgery), MFSTEd, CESR (UK) - HPB & LT | Consultant HPB and Multi Organ Transplant Surgeon Surgeon, Gleneagles Hospital (Fortis network), Chennai.
Last medically reviewed: July 2026

Read Time:

18 Mins

Key Takeaways

What This Guide Covers